natgillin/translations-raw huggingface dataset:
In B-ALL patients with relapse within 18 months of diagnosis (n = 27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62).
Pri bolnikih z B- celično ALL in relapsom v manj kot 18 mesecih po diagnozi (n = 27) je bil delež popolnih odgovorov 67% (95% CI: 46, 84) in delež 4-mesečnega preživetja bolnikov brez dogodkov 44% (95% CI: 26, 62).
In B-ALL patients with relapse within 18 months of diagnosis (n = 27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62).
Pri bolnikih z B-celično ALL in relapsom v manj kot 18 mesecih po diagnozi (n = 27) je bil delež popolnih odgovorov 67 % (95% CI: 46, 84) in delež 4-mesečnega preživetja bolnikov brez dogodkov 44 % (95% CI: 26, 62).
In B-precursor ALL, certain cells that give rise to B-cells (a type of white blood cell) multiply too quickly and eventually these abnormal cells replace normal blood cells.
Pri akutni limfoblastni levkemiji predhodniških celic B se določene celice, iz katerih nastajajo celice B (vrsta belih krvničk), razmnožujejo prehitro, zaradi česar te nenormalne celice sčasoma nadomestijo normalne krvne celice.
In babies and young children (aged 0-2 years) hereditary fructose intolerance (HFI) may not yet be diagnosed and may be fatal, thus, they must not receive this medicinal product.
Pri dojenčkih in majhnih otrocih (starih od 0–2 leti) morda še ni bila postavljena diagnoza dedne intolerance za fruktozo (HFI - hereditary fructose intolerance), ki je lahko smrtna, zato ne smejo prejemati tega zdravila.
In babies and young children (aged 0-2 years) hereditary fructose intolerance may not yet be diagnosed and may be fatal, thus, they must not receive this medicine (see special warnings about excipients at the end of this section).
Pri dojenčkih in majhnih otrocih (starih od 0–2 leti) morda še ni bila postavljena diagnoza dedne intolerance za fruktozo ki je lahko smrtna, zato ne smejo prejemati tega zdravila (glejte posebna opozorila o pomožnih snoveh na koncu tega poglavja).
In babies and young children (aged 0-2 years) hereditary fructose intolerance may not yet be diagnosed and may be fatal, thus, they must not receive this medicine (see special warnings about excipients at the end of this section).
Pri dojenčkih in majhnih otrocih (starih od 0–2 leti) morda še ni bila postavljena diagnoza dedne intolerance za fruktozo, ki je lahko smrtna, zato ne smejo prejemati tega zdravila (glejte posebna opozorila o pomožnih snoveh na koncu tega poglavja).
In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2 - 3 days after vaccination.
pri zelo prezgodaj rojenih nedonošenčkih (v 28. tednu nosečnosti ali prej) so lahko 2 do 3 dni po cepljenju razmiki med vdihi daljši kot normalno. otekanje ene ali obeh spodnjih okončin.
in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination
pri zelo prezgodaj rojenih dojenčkih (28. teden nosečnosti ali prej) se lahko 2 do 3 dni po cepljenju pojavijo daljši presledki med dihi, kot je običajno,
in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.
pri zelo prezgodaj rojenih dojenčkih (28. teden nosečnosti ali prej) se lahko 2 do 3 dni po cepljenju pojavijo daljši presledki med dihi, kot je običajno,
in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination. children with a rare inherited illness called Severe Combined Immunodeficiency (SCID) may have an inflamed stomach or gut (gastroenteritis) and pass the vaccine virus in their stools.
pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred ali v 28. tednu nosečnosti) se lahko v dveh do treh dneh po cepljenju pojavijo med vdihi daljši presledki kot je normalno otroci z redko dedno boleznijo, imenovano huda kombinirana imunska pomanjkljivost (SCID) lahko dobijo vnetje želodca ali črevesja (gastroenteritis) in izločajo virus iz cepiva z blatom.
in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination. children with a rare inherited illness called Severe Combined Immunodeficiency (SCID) may have an inflamed stomach or gut (gastroenteritis) and pass the vaccine virus in their stools.
pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred ali v 28. tednu nosečnosti) se lahko v dveh do treh dneh po cepljenju pojavijo med vdihi daljši presledki kot je normalno. otroci z redko dedno boleznijo, imenovano huda kombinirana imunska pomanjkljivost (SCID) lahko dobijo vnetje želodca ali črevesja (gastroenteritis) in izločajo virus iz cepiva z blatom.
In bicalutamide-controlled trials, 3 patients (0.8%) out of 380 chemotherapy-naïve patients treated with enzalutamide and 1 patient (0.3%) out of 387 receiving bicalutamide experienced a seizure.
V z bikalutamidom nadzorovanih preskušanjih so se konvulzije pojavile pri treh (0,8 %) od 380 bolnikov, ki se predhodno še niso zdravili s kemoterapijo, zdravljenih z enzalutamidom, in en bolnik (0,3 %) od 387 bolnikov, ki so prejemali bikalutamid.
In biological tissue, nitric oxide may form peroxynitrite with superoxide (O -), an unstable compound which may cause tissue damage through further redox reactions.
Dušikov oksid v tkivih lahko s superoksidom (O2-) tvori peroksinitrit, nestabilno spojino, ki lahko z nadaljnjimi reakcijami oksidacije in redukcije povzroči poškodbe tkiv.
In boceprevir-treated subjects who did not attain sustained virologic response (SVR) for whom samples were analyzed, 53% had post- baseline RAVs detected.
Med preiskovanci, ki so prejemali boceprevir in niso dosegli trajnega virološkega odziva (SVR), a so imeli opravljeno analizo vzorcev, jih je imelo RAV v obdobju po začetku zdravljenja 53 %.
In bone, the content increases from 0.01%ID/g at 5 min to 0.23%ID/g after 12 hours.
V kosteh se vsebnost poveča z 0,01 % ID/g po 5 minutah na 0,23 % ID/g po 12 urah.
In both adolescents and adults, Nimenrix was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as defined above (Table 11).
Cepivo Nimenrix je bilo pri mladostnikih in pri odraslih imunološko neinferiorno cepivu ACWY-PS, kar zadeva odziv na cepivo, kot je definiran zgoraj (preglednica 11).
In both adults and children with an average of 50% body surface area treated, systemic exposure (i.e.
Tako pri odraslih kot pri otrocih s povprečno 50% zdravljene telesne površine je sistemska izpostavljenost (tj.
In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours received tamoxifen 20 mg once a day for up to 5 years.
V obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale tamoksifen 20 mg na dan.
In both arms, after the last cycle of chemotherapy, patients with ER+ and/or PgR+ tumours received tamoxifen 20 mg once a day for up to 5 years.
V obeh krakih so bolnice s tumorji, ki so imeli pozitivne ER in/ali PgR, po zadnjem ciklusu kemoterapije do 5 let prejemale tamoksifen 20 mg enkrat na dan.
In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
V obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale 20 mg tamoksifena dnevno.
In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
V obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale tamoksifen 20 mg na dan.
In both AS studies, Cosentyx-treated patients (150 mg in AS Study 2 and both regimens in AS Study 1) demonstrated significantly improved signs and symptoms at Week 16, with comparable magnitude of response and efficacy maintained up to Week 52 in both anti-TNFα-naive and anti-TNFα-IR patients.
V obeh študijah ankilozirajočega spondilitisa je pri bolnikih, ki so prejemali zdravilo Cosentyx (v odmerku 150 mg v 2. študiji ankilozirajočega spondilitisa in pri obeh režimih zdravljenja v 1. študiji ankilozirajočega spondilitisa), po 16 tednih prišlo do statistično značilnega izboljšanja znakov in simptomov, pri čemer je bila izraženost odziva primerljiva med skupinama predhodno nezdravljenih in z zaviralci TNFα neodzivnih bolnikov, učinkovitost pa se je v obeh podskupinah ohranila do konca 52 tedna.
In both bovine and porcine polymorphonuclear cells (PMNs; neutrophils), tulathromycin promotes apoptosis (programmed cell death) and the clearance of apoptotic cells by macrophages.
Pri obeh, govejih in prašičjih polimorfonuklearnih celicah (neutrofilci), tulatromicin spodbuja apoptozo (programirana celična smrt) in očiščenje apoptotskih celic z makrofagi.
In both cases, on the following day you should use a new patch at the usual time.
Naslednji dan v obeh primerih zamenjajte obliž z novim ob običajnem času.
In both cases, phenylalanine cannot be effectively transformed into the amino acid tyrosine, leading to increased phenylalanine levels in the blood.
V obeh primerih se fenilalanin ne more učinkovito pretvoriti v aminokislino tirozin, kar vodi do povečanih ravni fenilalanina v krvi.
In both cases, treatment with canagliflozin may be restarted once the patient’s condition has stabilised.
V obeh primerih se lahko zdravljenje s kanagliflozinom ponovno uvede, ko je stanje bolnikov stabilizirano.
In both cases, treatment with dapagliflozin may be restarted once the patient’s condition has stabilised.
V obeh primerih je mogoče dapagliflozin znova uvesti, ko se bolnikovo stanje stabilizira.
In both cases, treatment with empagliflozin may be restarted once the patient’s condition has stabilised.
V obeh primerih je mogoče zdravljenje z empagliflozinom nadaljevati, ko se stanje bolnika stabilizira.
In both cases, treatment with Vokanamet may be restarted once the patient’s condition has stabilised.
V obeh primerih se lahko zdravljenje z zdravilom Vokanamet ponovno uvede, ko je stanje bolnikov stabilizirano.
In both cats and dogs the most common side effects are local reactions at the site of application, such as temporary itchiness, and on rare occasions, greasy fur and redness of the skin.
Pri mačkah in psih so najpogostejši neželeni učinki lokalne reakcije na mestu nanosa zdravila, kot so začasno srbenje ter v redkih primerih mastna dlaka in pordelost kože.
In both groups a decrease in body weight was seen: –2.4 kg with liraglutide vs –1.09 kg with placebo.
V obeh skupinah so ugotovili zmanjšanje telesne mase; -2,4 kg z liraglutidom in -1,09 kg s placebom.
In both INPULSIS trials, the risk of progression was statistically significantly reduced for patients treated with nintedanib compared with placebo.
V obeh preskušanjih INPULSIS se je tveganje za napredovanje bolezni statistično pomembno zmanjšalo pri bolnikih, zdravljenih z nintedanibom, v primerjavi s placebom.
In both of the pivotal 12-week and 24-week studies, Incruse demonstrated statistically significant and clinically meaningful improvements in lung function (as defined by change from baseline trough FEV1 at Week 12 and Week 24 respectively, which was the primary efficacy endpoint in each study) compared with placebo (see Table 1).
Tako 12-tedenska kot 24-tedenska ključna študija sta pokazali, da je zdravilo Incruse v primerjavi s placebom statistično značilno in klinično pomembno izboljšalo delovanje pljuč (opredeljeno kot sprememba FEV1 od izhodišča do 12. oziroma 24. tedna; to je bil primarni opazovani dogodek učinkovitosti v obeh študijah) (glejte preglednico 1).
In both of these circumstances a replacement implant should be administered.
V obeh primerih je treba namestiti nadomesten implantat
In both of these circumstances a replacement implant should be administered.
V obeh primerih je treba namestiti nadomesten implantat.
In both of these circumstances a replacement implant should be administered.
V obeh primerih je treba uporabiti nadomestni implantat
In both of these studies tenofovir disoproxil fumarate was significantly superior to adefovir dipivoxil for the primary efficacy endpoint of complete response (defined as HBV DNA levels < 400 copies/ml and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis).
V obeh študijah je bil dizoproksiltenofovirijev fumarat pomembno učinkovitejši od dipivoksiladefovirata v primarnem cilju učinkovitosti študije, popolnemu odzivu (opredeljeni kot ravni HBV DNA < 400 kopij/ml in izboljšanju za vsaj 2 točki na Knodellovi nekroinflamatorni lestvici (Knodell Necroinflammatory Score) brez poslabšanja na Knodellovi fibrozni lestvici (Knodell Fibrosis)).
In both placebo-controlled and open-label follow-up clinical trials for rheumatoid arthritis, cases of lupus- like syndrome were reported uncommonly.
V s placebom nadzorovanih in v odprtih sledilnih kliničnih študijah za revmatoidni artritis so občasno poročali o lupusu podobnem sindromu.
In both RAISE and TRA100773B the response to eltrombopag relative to placebo was similar irrespective of ITP medicinal product use, splenectomy status and baseline platelet count (≤ 15,000/µl, > 15,000/µl) at randomisation.
V obeh študijah, RAISE in TRA100773B, je bil odziv na eltrombopag v primerjavi s placebom podoben, ne glede na uporabo zdravila za zdravljenje ITP, status splenektomije in izhodiščno število trombocitov (≤ 15.000/µl, > 15.000/µl) v času randomizacije.
In both schedules, a booster response indicative of immunological priming was observed for each vaccine serotype (Table 7 and Table 8).
Pri obeh časovnih razporedih so zabeležili odziv na obnovitveni odmerek za vsak serotip v cepivu (preglednica 7 in preglednica 8), kar kaže na imunološko pripravo.
In both species difloxacin may be conjugated (glucuronidated or sulphated), desmethylated into sarafloxacin or oxidised into N-oxide-difloxacin.
Pri obeh vrstah se difloksacin metabolizira v sarafloksacin (desmetil difloksacin) ali pa oksidira v N- oksid-difloksacin.
In both studies at Week 24, suppression of HIV RNA to less than 50 copies/ml was maintained in 84.4 % of the raltegravir group versus 90.6 % of the lopinavir (+) ritonavir group, (Non-completers = Failure).
V obeh študijah se je v 24. tednu supresija HIV RNA na manj kot 50 kopij/ml ohranila pri 84,4 % bolnikov v skupini, ki je prejemala raltegravir, in pri 90,6 % bolnikov v skupini, ki je prejemala lopinavir (+) ritonavir (z uporabo metode nedokončanje = neuspeh).
In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 – 13.7%, (p<0.001).
V obeh študijah je bil esomeprazol 20 mg pomembno boljši v primerjavi s placebom pri primarnem opazovanem dogodku, popolnem prenehanju zgage, opredeljenem kot odsotnost epizod zgage v zadnjih 7 dneh pred končnim obiskom (33,9–41,6 % v primerjavi s placebom 11,9–13,7 % (p < 0,001)).
In both studies LEVP 2006-1 and LEVP 2006-4, administration of Cinryze resulted in increases in antigenic and functional C1 inhibitor levels post-infusion compared to pre-infusion values, with similar trends observed in children and adults.
V obeh študijah, LEVP 2006-1 and LEVP 2006-4, je uporaba zdravila Cinryze zvečala ravni antigenskega in funkcionalnega inhibitorja C1 po infuzijah v primerjavi z vrednostmi pred infuzijami, pri čemer so bili trendi, ki so jih ugotovili pri otrocih in odraslih, podobni.
In both studies most events were mild to moderate in severity.
V obeh preskušanjih je bila po resnosti večina dogodkov blagih do zmernih.
In both studies of the solution for injection, patients receiving Abilify had a greater reduction in symptoms of agitation than those receiving placebo.
V obeh študijah raztopine za injiciranje je pri bolnikih, ki so prejemali zdravilo Abilify, prišlo do večjega zmanjšanja simptomov agitacije kot pri tistih, ki so prejemali placebo.
In both studies one third of the patients in average had Sjögren’s syndrome; as for the overall population, a statistically significant improvement in CFS in favour of IKERVIS was observed in this subgroup of patients.
V obeh študijah je imela Sjögrenov sindrom povprečno ena tretjina bolnikov; kot za celotno populacijo so tudi za to podskupino bolnikov opazili statistično značilno izboljšanje po CFS v korist zdravila IKERVIS.
In both studies spironolactone use was not allowed as spironolactone binds to the androgen receptor and may increase PSA levels.
Spironolakton v obeh študijah ni bil dovoljen, ker se veže na androgene receptorje in zato lahko zveča koncentracije PSA.
In both studies the clearance rates were higher after illumination with narrow light spectrum devices but the incidence and intensity of administration site disorders (e.g. transient pain, erythema) increased in patients illuminated with these devices (see tables above and section 4.8).
V obeh študijah so bile stopnje odstranitve lezij večje po osvetlitvi z napravami s svetlobo ozkega spektra, vendar pa sta se pojavnost in intenzivnost motenj na mestu nanosa (npr. prehodna bolečina, eritem) povečali pri bolnikih, osvetljenih s temi napravami (glejte preglednico zgoraj in poglavje 4.8).
In both studies the treatment duration was 48 weeks, with 24 weeks of treatment-free follow-up.
V obeh študijah je zdravljenje potekalo 48 tednov, ki jim je sledilo 24-tedensko obdobje sledenja bolnikom brez jemanja zdravil.
In both studies the treatment lasted for three months (1 treatment course):
V obeh študijah je zdravljenje trajalo tri mesece (en ciklus zdravljenja).
In both studies, 6 months treatment with Xadago increased the time during the day during which patients were ‘on’ and able to move by 30-60 minutes when compared with placebo.
V obeh študijah je 6-mesečno zdravljenje z zdravilom Xadago v primerjavi s placebom za 30 do 60 minut tekom dneva podaljšalo čas „vklopa“, ko so se bolniki lahko gibali.
In both studies, a total of 347 patients were randomized and received OZURDEX and 350 patients received sham.
V obeh študijah je bilo naključno izbranih 347 bolnikov, ki so prejemali zdravilo OZURDEX, in 350 bolnikov, ki so prejemali placebo.
In both studies, ambrisentan was added to patients’ supportive/background medication, which could have included a combination of digoxin, anticoagulants, diuretics, oxygen and vasodilators (calcium channel blockers, ACE inhibitors).
V obeh študijah so ambrisentan uvedli dodatno k podpornemu/osnovnemu zdravljenju, ki je lahko vključevalo kombinacijo digoksina, antikoagulantov, diuretikov, kisika in vazodilatatorjev (zaviralci kalcijevih kanalčkov, zaviralci ACE).
In both studies, decreases in HbA1c were evident in both treatment groups as early as the first post-treatment HbA1c measurement (weeks 4 or 6).
V obeh študijah je prišlo do znižanja HbA1c pri obeh skupinah že pri prvem merjenju HbA1c po začetku zdravljenja (4. in 6. teden).
In both studies, dose adjustments were allowed based on clinical and laboratory finding.
V obeh študijah so bile dovoljene prilagoditve odmerka glede na klinične in laboratorijske izvode.
In both studies, Duloxetine Lilly 60 mg once daily and 60 mg twice daily significantly reduced pain compared with placebo.
V obeh študijah je zdravilo Duloxetine Lilly 60 mg enkrat na dan in 60 mg dvakrat na dan značilno zmanjšalo bolečino v primerjavi s placebom.
In both studies, Duloxetine Lilly 60 mg once daily and 60 mg twice daily significantly reduced pain compared with placebo.
V obeh študijah je zdravilo Duloxetine Lilly60 mg enkrat na dan in 60 mg dvakrat na dan značilno zmanjšalo bolečino v primerjavi s placebom.
In both studies, Eliquis was compared with enoxaparin (another medicine used to prevent blood clots).
V obeh študijah so zdravilo Eliquis primerjali z enoksaparinom (drugim zdravilom, ki se uporablja za preprečevanje krvnih strdkov).
In both studies, frequency, type and severity of adverse reactions observed in children and adolescents have been generally consistent with those observed in adults, with the exception of infections which were reported at a higher frequency, especially in children below the age of 3 years.
V obeh študijah so se pogostnost pojavljanja, vrsta in stopnja izraženosti neželenih učinkov, ki so jih opažali pri otrocih in mladostnikih, večinoma ujemale s tistimi, ki so jih opažali pri odraslih, z izjemo okužb, o katerih so poročali pogosteje, zlasti pri otrocih, mlajših od 3 let.
In both studies, it decreased the severity of the subject’s most bothersome baseline VVA symptom, decreased vaginal pH, decreased the percentage of vaginal parabasal cells from the maturation index (MI) and increased the percentage of vaginal superficial cells from the MI.
V obeh študijah je zdravilo FABLYN zmanjšalo stopnjo izraženosti najbolj motečega simptoma VVA bolnice ob začetku študije, znižanega nožničnega pH, zmanjšalo odstotni delež vaginalnih parabazalnih celic iz indeksa dozorevanja (MI-maturation index) in zvečalo odstotni delež vaginalnih površinskih celic iz MI.
In both studies, more patients had a partial response to Atriance treatment, with blood counts returning towards normal levels.
V obeh študijah se je več bolnikov delno odzvalo na zdravljenje z zdravilom, pri čemer se je število krvnih celic približalo normalni ravni.
In both studies, patients adding Azilect spent an average of around one hour less in the ‘off’ state than those adding placebo.
V obeh študijah je bil pri bolnikih, ki so dodatno prejemali zdravilo Azilect, čas stanja „off“ v povprečju približno eno uro krajši kot pri bolnikih, ki so kot dodatek prejemali placebo.
In both studies, patients had advanced terminal illness and limited life expectancy, with the majority having a primary diagnosis of incurable cancer; other primary diagnoses included end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer’s disease/dementia, HIV/AIDS, or other advanced illnesses.
V obeh študijah so imeli bolniki napredovalo terminalno bolezen in krajšo pričakovano življenjsko dobo, večina jih je imela primarno diagnozo neozdravljivega raka; med drugimi primarnimi diagnozami so bili še končni stadij KOPB/emfizema, kardiovaskularne bolezni/popuščanja srca, Alzheimerjeve bolezni/demence, HIV/AIDS in drugih napredovalih bolezni.
In both studies, patients on bosentan were less likely to develop multiple new digital ulcers during the study and took longer to develop each successive new digital ulcer than did those on placebo.
V obeh študijah so bolniki, zdravljeni z bosetanom, med študijo razvili manj novih razjed na prstih in so potrebovali dlje, da so razvili vsako naslednjo razjedo kot bolniki, zdravljeni s placebom.
In both studies, patients taking Rasagiline ratiopharm spent an average of around one hour less in the ‘off’ state than those taking placebo.
V obeh študijah so bolniki, ki so prejemali zdravilo Razagilin ratiopharm, preživeli v povprečju približno eno uro manj v stanju „izklopa“ kot bolniki, ki so prejemali placebo.
In both studies, patients were randomly assigned in a 3:2 ratio to either 2 mg Eylea administered every 4 weeks (2Q4), or the control group receiving sham injections every 4 weeks for a total of 6 injections.
V obeh študijah so bolnike naključno razporedili v razmerju 3:2 v skupino, ki je vsake 4. tedne prejemala 2 mg zdravila Eylea (2Q4) ali v kontrolno skupino, ki je vsake 4 tedne prejemala injekcije placeba, skupno 6 injekcij.
In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to
V obeh študijah so bili bolniki stratificirani glede na začetno vrednost HIV-1 RNA (≤ 100.000 kopij/ml,
In both studies, patients were treated with prednisone or prednisolone together with either Zytiga or placebo.
V obeh študijah so bolniki poleg zdravila Zytiga oziroma placeba prejemali tudi prednizon ali prednizolon.